COVID-19 Saliva-based Screening Market Poised to Transform Diagnostic Landscape - Persistence Market Research

The COVID-19 pandemic triggered a transformative demand for diagnostic solutions globally, and saliva-based screening emerged as a pivotal technology in the fight against SARS-CoV-2. Unlike conventional nasopharyngeal swabs, saliva-based testing provides a less invasive, more patient-friendly, and cost-effective alternative, making it highly suitable for mass screening and repeated testing scenarios. The global market for COVID-19 saliva-based screening is projected to witness a gradual decline over the forecast period, reflecting the increasing global vaccination coverage and a shift toward preventive healthcare rather than reactive testing.

According to Persistence Market Research, worldwide revenue from the COVID-19 saliva-based screening market reached US$ 2.1 billion in 2022, representing a rapid growth phase during the peak pandemic years. However, the market is expected to experience a CAGR of -1.5%, reaching approximately US$ 1.6 billion by 2033. Despite the projected decline, saliva-based detection kits remain the leading product segment, accounting for 82.8% of the market in 2022, indicating strong consumer preference and technological adoption. Geographically, the United States dominates the market due to high healthcare expenditure, widespread government support for COVID-19 testing programs, and the presence of key diagnostic companies. Emerging economies such as China and India are also gaining traction, driven by rising infection rates and increasing demand for accessible home-based testing solutions.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/32712

Key Highlights from the Report

• COVID-19 saliva-based detection kits accounted for 82.8% of the global market in 2022.
• The U.S. held the largest regional market share at 31.7% in 2022.
• RT-qPCR technology dominates revenue generation due to its high sensitivity and specificity.
• Diagnostic laboratories contributed the highest end-user share with 26.9% globally.
• Home-based testing is emerging as a major driver for saliva-based COVID-19 detection.
• China and India are witnessing accelerated adoption due to high infection prevalence and low vaccine coverage.

Market Segmentation

The COVID-19 saliva-based screening market can be segmented based on product type, technology, end-user, and application. By product type, saliva-based detection kits dominate, given their ease of use, non-invasiveness, and suitability for self-collection. PCR-based kits are the primary technology segment, providing high accuracy and sensitivity, while antigen and antibody-based rapid tests are increasingly popular for large-scale and point-of-care testing. By end-user, diagnostic laboratories hold the highest market share due to their capacity for high-throughput testing and access to advanced laboratory equipment. Hospitals and clinics follow closely, leveraging saliva-based tests for patient triaging and rapid diagnosis. Home-based testing kits are gaining momentum, particularly in regions emphasizing self-detection to reduce exposure risk and healthcare workload. By application, COVID-19 diagnostics dominate, supported by growing awareness, mandatory testing policies, and increased infection monitoring in workplaces, educational institutions, and public spaces.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/covid-19-saliva-based-screening-market.asp

Regional Insights

Regionally, the COVID-19 saliva-based screening market is led by North America, with the United States at the forefront due to robust government funding, a high prevalence of COVID-19 cases, and a well-established healthcare infrastructure. Asia-Pacific is emerging as a critical market, with China capturing 89.1% of East Asia's market share in 2022, driven by rising infection rates, limited vaccine efficacy against variants, and expanding public testing initiatives. India is also notable in South Asia, holding 75.7% of the regional market. Increasing awareness of self-testing, high patient demand, and overburdened healthcare facilities during pandemic waves have driven the adoption of saliva-based screening solutions. Europe maintains steady demand, particularly in countries with aging populations and stringent testing regulations, while Latin America and the Middle East are gradually expanding due to government-led testing programs and growing public health awareness.

Market Drivers

The growth of the COVID-19 saliva-based screening market has been primarily fueled by the high incidence of COVID-19 infections globally. Saliva-based tests offer a less invasive and more convenient testing option, enabling higher compliance among patients, especially children, elderly individuals, and those with mobility constraints. Additionally, these tests reduce healthcare worker exposure, require minimal technical training, and eliminate the need for expensive swabs and personal protective equipment, making testing programs more sustainable and cost-effective. Emerging virus variants and periodic surges in infection rates continue to drive the need for frequent testing, while public and private investments in diagnostic infrastructure have accelerated research and development in saliva-based detection technologies.

Market Restraints

Despite its advantages, the market faces several constraints. The widespread rollout of COVID-19 vaccines has significantly reduced the demand for routine testing in many regions, particularly among vaccinated populations. Competition from other specimen-based testing methods, such as nasopharyngeal swabs, blood tests, and rapid antigen tests, also limits market growth. Furthermore, inconsistent testing regulations, quality concerns over at-home kits, and fluctuating infection rates contribute to market uncertainty. Healthcare systems in low-resource regions may still rely on traditional methods, delaying widespread adoption of saliva-based solutions.

Market Opportunities

Several opportunities exist for market expansion, particularly in developing regions. Self-collection and home-based testing present significant growth potential, especially as consumers increasingly prioritize convenience and safety. Integration of saliva-based diagnostics with mobile health technologies, telemedicine platforms, and AI-driven analytics could enhance testing efficiency and data management. Additionally, the rise of workplace and educational screening programs provides an avenue for mass testing kits. Innovations in multiplex testing for simultaneous detection of COVID-19 and other respiratory infections can further increase the utility of saliva-based tests and drive market growth over the next decade.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/32712

Company Insights

The COVID-19 saliva-based screening market is highly competitive, with several leading players actively expanding their portfolios and geographic reach. Prominent companies include:

• Thermo Fisher Scientific
• Qiagen
• Hologic
• Takara Bio Inc
• Arcis Biotechnology Limited
• GeneProof
• Abacus ALS
• Chai Inc.
• Kolplast Group
• Lucence Health Inc
• Vitagene
• Therma Bright Inc
• ACON Laboratories, Inc
• Norgen Biotek Corp.
• Assure Tech. (Hangzhou) Co., Ltd
• Beijing Hotgen Biotech Co., Ltd
• Nantong Diagnos Biotechnology Co., Ltd
• NeuMoDx Molecular, Inc.
• KYODO INTERNATIONAL INC.
• Canvax
• Zymo Research Corporation
• Salimetrics
• NEST Scientific USA
• Miraclean Technology Co. Ltd
• Mawi DNA Technologies
• Cell Projects Ltd.

Key Segments of the COVID-19 Saliva-based Screening Industry Research

Product:

Saliva Collection Kits
Saliva Nucleic Acid Purification Kits
Saliva-based Detection Kits
Rapid Test Kits
PCR-based Kits

Technology:

Direct Sample to PCR
RT-qPCR
Lateral Flow Assays

Application:

COVID-19 Research
COVID-19 Diagnostics

End User:

Diagnostic Laboratories
Hospitals & Clinics
Academic and Research Institutes
Biopharma Companies
Long Term Care Facilities
Home Care Settings
Others

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Recent Developments:

In March 2020, Abbott launched ID NOW, a portable molecular POCT device capable of delivering COVID-19 test results in under five minutes.

Chembio Diagnostics, Inc. introduced an FDA Emergency Use Authorized POCT for COVID-19 in April 2021, expanding both standard and decentralized diagnostic testing capabilities.

Conclusion

The COVID-19 saliva-based screening market has evolved rapidly, driven by urgent global demand for accessible, non-invasive, and reliable diagnostic solutions. While the market is projected to experience a moderate decline due to increasing vaccination coverage and the emergence of alternative testing methods, saliva-based detection continues to hold significant relevance in self-testing, diagnostic laboratories, and point-of-care applications. Technological advancements, cost-effective testing, and rising awareness of home-based solutions provide avenues for sustained growth, particularly in emerging economies such as India and China. As healthcare systems adapt to the ongoing challenges posed by viral variants, saliva-based screening is poised to remain a crucial component of comprehensive COVID-19 monitoring strategies worldwide.

Read More Related Reports:

Wound Healing Ointment Market https://www.persistencemarketresearch.com/market-research/wound-healing-ointment-market.asp
Medicated Soap Market https://www.persistencemarketresearch.com/market-research/medicated-soap-market.asp
First Aid Kit Market https://www.persistencemarketresearch.com/market-research/first-aid-kit-market.asp
Pain Relief Patches Market https://www.persistencemarketresearch.com/market-research/pain-relief-patches-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.